Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions-Reference-Cited by-同舟云学术

Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

Published:2023-10-18 Issue: Volume: Page:1-9
ISSN:1946-6315
Container-title:Statistics in Biopharmaceutical Research
language:en
Short-container-title:Statistics in Biopharmaceutical Research

Author:

Uschner Diane¹^ORCID,Sverdlov Oleksandr²^ORCID,Carter Kerstine³^ORCID,Chipman Jonathan⁴⁵^ORCID,Kuznetsova Olga⁶,Renteria Jone¹,Lane Adam⁷,Barker Chris⁸,Geller Nancy⁹,Proschan Michael¹⁰,Posch Martin¹¹^ORCID,Tarima Sergey¹²^ORCID,Bretz Frank¹¹¹³^ORCID,Rosenberger William F.¹⁴

Affiliation:

1. Biostatistics Center & Department of Biostatistics and Bioinformatics, George Washington University, Rockville, MD

2. Novartis Pharmaceuticals Corporation, East Hanover, NJ

3. Boehringer-Ingelheim Pharma, Ridgefield, CT

4. Intermountain Healthcare Department of Population Health Sciences Division of Biostatistics, University of Utah, Salt Lake City, UT

5. Huntsman Cancer Institute, Cancer Biostatistics, University of Utah, Salt Lake City, UT

6. Merck & Co., Inc., Rahway, NJ

7. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

8. Statistical Planning and Analysis Services, Inc, San Carlos, CA

9. National Heart Lung and Blood Institute, Bethesda, MD

10. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD

11. Center for Medical Statistics, Section for Medical Statistics, MedUni Vienna, Vienna, Austria

12. Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI

13. Analytics, Novartis Pharma AG, Basel, Switzerland

14. Department of Statistics, George Mason University, Fairfax, VA

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/19466315.2023.2257894

Reference30 articles.

1. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

2. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures

3. Regulatory Guidance on Randomization and the Use of Randomization Tests in Clinical Trials: A Systematic Review

4. “A Remark on Randomization in Clinical Trials,”;Cox D. R.;Utilitas Mathematica,1982

5. New Orleans researchers fight to salvage work from submerged labs

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Stratification Strategies for Population‐ Versus Randomization‐Based Inference;Pharmaceutical Statistics;2024-07-10

2. Randomization-Based Inference for Clinical Trials with Missing Outcome Data;Statistics in Biopharmaceutical Research;2023-09-27